PPARG and metabolic dysfunction-associated steatohepatitis: Above this, peroxisome proliferator activated receptor (PPAR)γ agonist (i.e., piogliazone) has shown therapeutic potentials in patients with NAFLD, particularly nonalcoholic steatohepatitis (NASH), or T2DM, and other treatments with vitamin E, statins, or silymarin are also reported to contribute to improvement in NAFLD; however, these treatments have side effects or little evidence to support their clinical uses in NAFLD [15].